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Pathogenesis and clinical course of mixed calcium oxalate and uric acid
nephrolithiasis. By direct measurement, urine from patients who form
calcium oxalate stones was supersaturated abnormally with respect to
calcium oxalate monohydrate but not supersaturated with respect to
undissociated uric acid. Urine from patients who form uric acid stones
was supersaturated excessively with undissociated uric acid but not
calcium oxalate. Patients who form both calcium oxalate and uric acid
stones, however, produce urine that is supersaturated with respect to
both solid phases. Low urine pH was the primary factor that increased
supersaturation with respect to undissociated uric acid. The formation
of both calcium oxalate and uric acid stones appears to be explained by
a dual abnormality of urine supersaturation.
Pathogenie et evolution clinique de Ia lithiase urinaire mixte d'oxalate
de calcium et d'acide urique. Par mesure directe il a été observe que les
urines de malades formant des calculs d'oxalate de calcium étaient
anormalement sursaturées en oxalate monohydrate de calcium, mais
non sursaturées en acide urique non dissocié. Les urines de malades
formant des calculs d'acide urique étaient sursaturées de facon exces-
sive en acide urique non dissocié mais non en oxalate de calcium. Les
malades formant a Ia fois des calculs d'oxalate de calcium et d'acide
urique, cependant, produisent des urines qui sont sursaturées en ces
deux phases solides. Un pH urinaire bas était le facteur primaire qui
augmentait la sursaturation en acide urique indissocié. La formation de
calculs d'oxalate de calcium et d'acide urique semble étre expliquée par
une double anomalie de La sursaturation urinaire.
Some people form stones composed of calcium oxalate and
uric acid [1—3]. They suffer from two different forms of nephro-
lithiasis and differ from the majority of patients, who form renal
stones composed only of calcium oxalate [4, 51. They also differ
from the small group of patients who produce pure uric acid
stones [2, 6—91. Calcium oxalate supersaturation is greater than
normal in urine from patients who produce calcium oxalate
stones [101, whereas uric acid stones occur when urine undisso-
ciated uric acid concentration is increased by low urine pH or
low urine volume [2, 6—9].
One might expect that patients who form mixed calcium
oxalate and uric acid stones would produce urine that was
supersaturated abnormally with respect to both calcium oxalate
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and uric acid, but this plausible hypothesis has never been
tested. Twenty-three patients have been described with mixed
calcium oxalate and uric acid stones [11. Two were hypercal-
ciuric, 11 were hypercalciuric and hyperuricosuric, and 10 had
neither disorder; urine pH was extremely low in only one
patient. In other words, conventional measurements suggest
that calcium oxalate and uric acid supersaturation both could
have been increased but are insufficient to establish the actual
conditions in the urine.
In this study we report urine supersaturation measurements
with respect to calcium oxalate monohydrate and undissociated
uric acid in patients who formed mixed calcium oxalate and uric
acid stones, and compare them to measurements in calcium
oxalate and pure uric acid stone formers. Supersaturation
measurements clarify the reason why they form mixed calcium
oxalate and uric acid stones. We also present evidence that the
natural histories of calcium oxalate, mixed calcium oxalate and
uric acid, and pure uric acid stone disease differ from one
another.
Methods
Selection of patients. Of the 1348 patients in our series, 821
have formed at least one stone that contained only calcium
salts, predominantly calcium oxalate, 109 formed mixed calci-
um oxalate and uric acid stones, and 22 formed pure uric acid
stones. In a past study based on this series [Ill, we excluded
recurrent calcium stone formers who had specific diseases such
as primary hyperparathyroidism, enteric hyperoxaluria, heredi-
tary renal tubular acidosis, and other conditions such as Paget
disease, Cushing syndrome, sarcoidosis, acetazolamide use,
antacid excess, vitamin D excess, and exogenous glucocorti-
coid administration. In this study, we have included 152 pa-
tients with these specific diseases and have excluded only six
calcium stone-forming patients with hereditary renal tubular
acidosis, detailed elsewhere [12]. The 109 mixed calcium oxa-
late and uric acid stone formers were patients who formed
stones that contained both calcium oxalate and uric acid, or
formed at least one stone composed only of calcium salts,
predominantly calcium oxalate, and another composed only of
pure uric acid. Of the 109 patients, 101 formed recurrent stones.
Supersaturation measurements for calcium oxalate were avail-
able in 431 of the 821 calcium oxalate stone formers, 56 of the
109 mixed calcium oxalate and uric acid stone formers and 9 of
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the 22 uric acid patients. Undissociated uric acid concentration
was measured in virtually everyone, 811, 106 and 22 for calcium
oxalate, mixed calcium oxalate and uric acid, and pure uric acid
stone diseases, respectively. Therefore, both measurements
were available in 429, 55, and 9 of the three groups,
respectively.
Methods of evaluation. Before treatment every patient was
evaluated using a clinical and laboratory protocol, detailed
elsewhere [2, 41, in which 24-hr urine collections were obtained
on three or four occasions, on an out-patient basis, without
dietary modification. Corresponding blood samples were ob-
tained between 8 and 9 A.M. at the completion of each collec-
tion, with patients in the postabsorptive state. We measured
supersaturation with respect to calcium oxalate using the con-
centration product method [10]. Urine undissociated uric acid
concentration was calculated directly from total uric acid
concentration and the Henderson-Hasselbach equation using a
pK for the dissociation of the N-9 proton of 5.31 [13]. Previous-
ly, we reported the solubility of undissociated uric acid in
human urine, at 37° C, as 96 3 mg/liter [14]. Drugs that could
affect our results were discontinued at least 14 days before the
study. Prior radiographs and medical records were used to
assess past stone history. A complete physical examination was
performed.
The diagnostic criteria used here were detailed elsewhere [2,
4, 10—12, 14, 15]. Idiopathic hypercalciuria was defined by
normocalcemia, elevated [2, 4, 15, 161 daily urinary calcium
excretion above 300 mg (men), 250 mg (women), or 4 mg/kg
(either sex), and exclusion of other causes of hypercalciuria.
Hyperuricosuria was defined by urinary excretion rates of uric
acid above 800 mg (men) and 750 mg (women) [2, 4, 7, 15], and
hyperoxaluria [171 by an excretion rate above 45 mg/kg (either
sex). Primary hyperparathyroidism was defined by unexplained
hypercalcemia (serum calcium above 10.1 mg/dl in men or 10
mg/dl in women) and confirmed at surgery [18]. The other,
uncommon, specific diseases causing stones were diagnosed on
conventional clinical grounds [2, 17].
Activity of stone disease was quantified by clinical and
radiologic criteria. New stones were defined by passage, surgi-
cal removal, or radiographic visualization of stones absent on
prior radiographs. For each patient, pretreatment new stones
and the duration of the pretreatment interval between the first
stone and entry into the program were tabulated, and stone
formation rates were calculated as the ratio of stones to the
pretreatment interval.
Treatment of mixed calcium oxalate and uric acid stones.
Seventeen patients had idiopathic hypercalciuria, 20 had hyper-
uricosuria, and 23 had both disorders. In these patients, hyper-
calciuria was treated with thiazide (37 patients) or diet alone (3
patients) and hyperuricosuria by allopurinol (29 patients) or diet
alone (14 patients). Thiazide was given as trichlormethiazide, 2
mg twice daily; the dose was adjusted, if necessary, to reduce
calcium excretion to below the upper limits of normal. Dietary
therapy was assessed by reduction of calcium and uric acid
excretion to below the upper limits of normal. Six patients had
primary hyperparathyroidism and were treated by parathyroid-
ectomy. Their results have been included in a previous report
[18] concerning primary hyperparathyroidism. Thirty-one pa-
tients had no disorder; 10 were treated only by increased fluid
intake, 4 by reduced dietary calcium, purine and oxalate intake,
10 by thiazide, 2 by allopurinol, and 5 by thiazide and
allopurinol.
Treatment of uric acid stones. In all cases, 24-hr average
urine pH was increased to between 6 and 6.5 using alkali (0.5 to
2 mg/kg/24 hr) and increased fluid intake. Thirteen patients also
received either allopurinol (ten patients) or reduced purine
intake (three patients).
Follow-up. For this study, mixed calcium oxalate and uric
acid and pure uric acid stone formers were contacted individ-
ually, or, when available, the most recent records were ob-
tained from referring physicians. In each case, the treatment
interval was measured from entry into the program to the date
of the last direct contact either with us or the referring
physician.
Experimental design and statistical analysis. We compared
all available pretreatment clinical and laboratory findings in
patients with calcium oxalate, mixed calcium oxalate and uric
acid, and pure uric acid stones. Urine calcium, oxalate, and uric
acid were expressed by 24-hr excretion rates, concentrations,
and 24-hr excretion rates were normalized by the 24-hr excre-
tion of creatinine in each urine or by body weight (kilograms)
measured the morning the urine collection was completed.
Frequencies of events were compared using x2statistics; means
were compared using t tests without assumption of equal
variances in the two groups. All statistics were calculated by
computer in a conventional manner (BMDP programs, Univer-
sity of California, Los Angeles, California).
Laboratory methods. Urine and serum uric acid and calcium
concentrations were measured using the uricase method and
atomic absorption spectrophotometry, as described elsewhere
[4, 10, 11, 14]. Urine oxalate was measured by precipitation and
reduction by zinc metal to glycolate [19]. Urine calcium oxalate
supersaturation was measured by seeding urine with calcium
oxalate monohydrate crystals for 48 hr at 37° C, with mixing.
The ratio of the product of the calcium and oxalate concentra-
tions of the urine before to that after incubation, the concentra-
tion product ratio (CPR), is a good reflection of supersaturation
[10, 17]. Values of 1 indicate urine at the solubility limit for
calcium oxalate; values above 1 indicate supersaturation.
Results
Mixed calcium oxalate and uric acid stone formers produced
urine that was supersaturated equally with respect to both
calcium oxalate and undissociated uric acid (Fig. I). In con-
trast, calcium oxalate stone formers displayed increased super-
saturation mainly with respect to calcium oxalate (Fig. 1), but
not undissociated uric acid, whereas the opposite was true of
urine from pure uric acid stone formers. These conclusions are
unchanged if we consider only those patients for whom both
measurements were available (numbers of patients in Methods).
Values of CPR were 2.7 0.06, 2.21 0.09, and 1.84 0.17 for
calcium oxalate, mixed calcium oxalate and uric acid, and pure
uric acid (mixed calcium oxalate and uric acid and pure uric
acid vs. calcium oxalate, P < 0.001); values for undissociated
uric acid were 108 4, 185 15, and 248 50 mg/liter for the
three groups (mixed calcium oxalate and uric acid and pure uric
acid vs. calcium oxalate, P < 0.001).
Metabolic disorders occurred at different frequencies in the
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Fig. 1. Calcium oxalate and undissociated uric acid supersaturation in
stone ftrming patients. Values for CPR (open bars) of above I indicate
supersaturation (Methods). The solubility of undissociated uric acid
(hatched bars) in urine is 96 3 mg/liter [14], so supersaturation can be
calculated by dividing the concentrations by 96. The figure presents all
available measurements in patients with calcium oxalate, mixed calci-
um oxalate and uric acid, and pure uric acid stones. For CPR, there
were values from 431, 56, and 9 patients for calcium oxalate, mixed
calcium oxalate and uric acid, and pure uric acid stone formers,
respectively; corresponding numbers of patients providing undissociat-
ed uric acid values were 811, 106, and 22. All values are means SEM.
Symbol: *, value differs from mixed and uric acid stones, P < 0.001.
three groups (Table 1). Idiopathic hypercalciuria alone was less
frequent in mixed calcium oxalate and uric acid and pure uric
acid than calcium oxalate stone disease. Hyperuricosuria, alone
or with idiopathic hypercalciuria, was equally frequent in
calcium oxalate and mixed calcium oxalate and uric acid stone
formers, but hyperuricosuria alone occurred at a very high
frequency in uric acid stones. Average excretion rates for
calcium and uric acid (Table 2) reflect this pattern of diagnosis.
Urine calcium excretion and pH were lowest in the pure uric
acid and highest in the calcium oxalate group; the mixed
calcium oxalate and uric acid group was between the two. Uric
acid excretion was comparable for all three groups. Low urine
pH was mainly responsible for the higher concentrations of
undissociated uric acid found in the pure uric acid and mixed
calcium oxalate and uric acid groups (Table 2).
The three groups differed widely in their pretreatment clinical
characteristics (Table 3). Pure uric acid stone formers formed
the most stones per patient year at risk, calcium oxalate stone
formers the least; the mixed calcium oxalate and uric acid group
was in between the other two groups. The pure uric acid stone
formers also were oldest and had the shortest interval between
their first stone and entry into our program. Although they had
fewer morbid complications per stone, the pure uric acid group
had more hospitalizations and surgeries per 100 patient years at
risk than the other two groups simply because their stone
formation rate was very high. The mixed calcium oxalate and
uric acid group had more cystoscopies than the calcium oxalate
and pure uric acid groups, but fewer surgeries. The calcium
Table 1. Metabolic disorders in patients with calcium, uric acid, or
mixed calcium and uric acid stones
Calcium Mixed Uric acid
(821) (%) (109) (%) (22) (%)
Idiopathic hypercalciuria' 263 (32) 17 (16) 2 (9)
Hyperuricosuriaa 121 (15) 20 (18) 9 (41)
Bothb 114 (14) 23 (21) 2 (9)
Neither 191 (23) 31(28) 7 (32)
Primary hyperparathyroidism 41 (5) 6 (5) 0 (0)
Enteric hyperoxaluria 39 (5) 4 (4) 2 (9)
Drug-induced 41 (5) 4 (4) 0 (0)
Othera 11 (1) 4 (4) 0 (0)
oxalate group had the most infections (Table 3). Despite these
differences pretreatment, response of stones to treatment was
excellent in all three groups.
Discussion
Mixed calcium oxalate and uric acid stones seemed to occur
when uric acid and calcium oxalate supersaturations both were
elevated in a given patient. When high undissociated uric acid
supersaturation predominated pure uric acid stones were
formed, and the opposite was true for calcium oxalate stones.
As others have found [6—91, low urine pH was critical for
elevating urinary undissociated uric acid enough to permit pure
uric acid or mixed calcium oxalate and uric acid stones to form.
In our previous report of 23 patients [1], the average value of
urinary undissociated uric acid was 167 26 mg/liter, close to
that of the present series and above the solubility limit of 96 3
mg/liter [14].
In patients with calcium oxalate stones, urine was barely
supersaturated with undissociated uric acid whereas even a
modest degree of supersaturation, of the order of 1.7 times the
solubility limit, appeared to foster uric acid crystallization and
lead to mixed stones. In contrast, urine calcium oxalate super-
saturation exceeded the solubility limit by 1.75-fold even in
patients who formed pure uric acid stones. This suggests that
much greater supersaturation with calcium oxalate than uric
acid may be needed to promote crystal formation in urine. The
difference may be related to the fact that urine contains
inhibitors of calcium oxalate but not of uric acid crystallization
[20]. It is also consistent with the observation that the average
urine undissociated uric acid concentration in normal people is
57 8 mg/liter [14], below the solubility limit, whereas the
average CPR value we have observed for calcium oxalate in
normal people is between 1.84 0.24 [101 and 2.34 0.21 [20].
The same factors could explain why uric acid stone disease
resulted in the most stones per patient year at risk, calcium
oxalate stone disease the least, and mixed calcium oxalate and
uric acid stone disease was in between the two extremes. The
*
3.
2.5
2
1.5
1'
250
200
II*
N = 821
Calcium
stones
N = 109
Mixed
stones
N =22
Uric acid
stones
Abbreviations: calcium, patients who form calcium oxalate stones;150 mixed, patients who form calcium oxalate and uric acid stones; uric
acid, patients who form only uric acid stones.
a Distribution among the three groups differs from that expected by
chance alone, P <0.001.
100
b Distribution among the three groups differs from that expected by
chance alone, P < 0.05.
a Patients in this category exhibit with Paget disease, Cushing syn-
drome, and sarcoidosis.
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Table 2. Selected laboratory characteristicsa
lack of urinary inhibitors for uric acid crystallization could
permit rapid and frequent formation and growth of uric acid
crystals whenever the solubility limit for uric acid is exceeded,
whereas inhibitors that moderate the formation and growth of
calcium oxalate crystals may reduce stone formation even when
supersaturation is excessive. Another possible factor may be
the amounts of material present. At most, urine contains 30 to
50 mg/liter of oxalic acid 10], compared to 200 to 500 mg/liter of
undissociated uric acid [14].
The reduction of urine pH in mixed stone formers compared
to calcium oxalate stone formers is not large and could be
mainly of dietary origin. We have observed [14] that a high meat
diet causes not only hyperuricosuria but also an average urine
pH of 5.6, compared to 6.1 in stone formers who are only
hypercalciuric. Perhaps mixed calcium oxalate and uric acid
stones result when diet causes a subtle lowering of urine pH.
Alternatively, the lower urine pH may be due to an inherited
abnormality, as it is in gout [7, 8].
From a practical point of view, mixed calcium oxalate and
uric acid stone disease is common, and patients who have an
average urine undissociated uric acid level above 160 mg/liter
seem at risk for it. Urine pH should be measured along with 24-
hr uric acid excretion in all stone-forming patients, so that
undissociated uric acid concentration can be calculated [13, 14].
Combined treatment with alkali, to raise pH, reduced purine
intake or allopurinol for hyperuricosuria and thiazide [4, 19] or
reduced calcium intake for hypercalciuria appears to reduce
calcium stone recurrence.
Type of stones
Calcium Mixed Uric acid
Characteristic (821) (109) (22)
Serum creatinine, mg/d/ 0.98 0.01 1.02 0.02c 1.06 0.05
Serum uric acid, mgldl 5.70 0.04 6.38 0.14 5.96 0.33
Serum calcium, mgldl 9.48 0.01 9.55 0.43 9.35 O.06b
Serum phosphorus, mgldl 3.17 0.48 3.23 0.62 3.25 0.08
Urine volume, liter 1.59 0.06 1.53 0.05 1.51 0.12
Urine calcium, mg/24 hr 231 4 216 10 175 25d
mgIkgI24 hr 3.06 0.05 2.62 0.12a 2.12 0.28
Urine uric acid, g124 hr 700 40 665 20 669 40
Urine pH 6.0 0.4 5.7 0.4 5.5 0.4
Urine oxalate, mg124 hr 39 16 38 1 36 3
All values are mean SaM. Numbers of patients are in parentheses; abbreviations are the same as in Table I.
Value differs from mixed, P < 0.05.
Value differs from calcium, P < 0.05.
"Value differs from calcium, P < 0.01.
Value differs from calcium, P < 0.001.
Table 3. Clinical characteristics of the three patient groupsa
Type of stones
Characteristic Calcium Mixed Uric acid
Number of patients 82 1(197) 109(20) 22(4)
Number with multiple stones 646 101 17
Age at first stone, yr 36 0.5 36 1 46 3
Pretreatment interval, Pt yrc 5770 1072 88.2
Total recurrent stones 4946 1254 224
Recurrent stones/lOU pt yrs 85.7 1 l7a 254b.c
Hospitalizations/100 pt yrs 25.4 29.9a 31.7c
Cystoscopies/100 pt yrs 13.8 21.8a 19.2c
Infections/100 pt yrs 6.9 4.4 2.3c
Surgeries/100 Pt yrs 7.8 55a 10.2b,c
Treatment interval, pt yrs 313 71
Total new stones 48 12
Patients with new stones 13 2
Predicted stones 366 180
Percentage of patients stone free d 88 91
a Abbreviations are the same as in Table I. The number of females is in parentheses. All values are mean SENt.
Value differs from mixed, P < 0.001.
Value differs from calcium, P < 0.001.
"Percentage of patients stone free for this group [4, 11, 17] has averaged 89%.
Patient year equals total years between onset of first stone and institution of treatment for each patient multiplied
patients forming calcium oxalate, mixed calcium oxalate, and uric acid or pure uric acid stones.
by the total number of
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